Welcome to our dedicated page for PURPLE BIOTECH LTD. SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Purple Biotech Ltd. SEC filings document foreign private issuer current reports for a clinical-stage oncology biotechnology company and its PPBT American depositary shares. Recent Form 6-K filings attach press releases and corporate presentations covering CAPTN-3, IM1240 and IM1305, preclinical and toxicology data, oncology development plans, collaboration announcements, scientific advisory activity, operating results, and risk-related forward-looking disclosures.
The filing record also reflects capital-structure and market-status matters, including ADS ratio disclosures and Nasdaq minimum bid price compliance. The company’s 6-K reports are incorporated by reference into registration statements on Form F-3 and Form S-8, linking current reports to shelf registration and equity-plan disclosure frameworks.
Purple Biotech Ltd. reported that it has established a Scientific Advisory Board (SAB) to guide development of its CAPTN-3 tri-specific antibody immunotherapy platform. The SAB includes experts in T-cell engagers, NK and T cell biology, tumor immunology and clinical oncology, including leaders involved in foundational approved therapies.
CAPTN-3 is a platform of masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells, using proprietary capping technology to confine immune activation to the tumor microenvironment. Lead candidate IM1240 is advancing toward the clinic, while IM1305 remains in preclinical development.
Purple Biotech also highlights additional pipeline assets: CM24, a CEACAM1-blocking antibody that showed improved outcomes across all efficacy endpoints in a Phase 2 pancreatic ductal adenocarcinoma study, and NT219, a dual IRS1/2 and STAT3 inhibitor in a Phase 2 study for head and neck cancer.
PURPLE BIOTECH LTD. director Simcha Rock filed an initial ownership statement showing substantial equity-based compensation. He directly holds 3,207,690 Ordinary Shares, including 2,454,167 unvested restricted stock units that settle in shares. He also holds stock options to buy 300,000 shares at $0.059375 per share and 2,650,000 shares at $0.00309375 per share, with vesting schedules running through 2028 and expirations in 2028 and 2030. Each American Depositary Share currently represents 2,000 Ordinary Shares.
PURPLE BIOTECH LTD. director Suzana Zilberberg filed an initial ownership report showing her equity stake in the company. She directly holds 3,062,500 Ordinary Shares as of the reported date, including 2,454,167 unvested restricted stock units that will settle in Ordinary Shares.
She also holds stock options to purchase 112,500 Ordinary Shares at $0.126875 per share expiring on December 29, 2026, options for 300,000 Ordinary Shares at $0.059375 per share expiring on April 24, 2028, and options for 2,650,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030, with portions of these options vesting over time.
PURPLE BIOTECH LTD. director Agmon Ido filed an initial ownership report showing substantial equity exposure. He beneficially owns 3,093,860 Ordinary Shares, including 2,454,167 unvested RSUs that settle in Ordinary Shares, and holds stock options over an additional 2,950,000 Ordinary Shares at low exercise prices.
PURPLE BIOTECH LTD. Chief Executive Officer Gil Efron reported his initial ownership, showing direct holdings of 15,750,000 Ordinary Shares. This includes 12,375,000 unvested restricted stock units that vest over time and are settled in Ordinary Shares, which may be represented by American Depositary Shares, each currently equal to 2,000 Ordinary Shares.
He also holds stock options to purchase 1,500,000 Ordinary Shares at $0.095054688 per share expiring on May 23, 2027; 3,750,000 Ordinary Shares at $0.0765625 per share expiring on July 11, 2027; and 13,500,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030, with 1,125,000 already vested and the remaining 12,375,000 vesting in equal quarterly installments until October 21, 2028.
PURPLE BIOTECH LTD. Chief Financial Officer Shai S. Lankry has updated his reported equity holdings. The filing shows stock options to purchase 3,000,000 ordinary shares under one grant and 3,550,000 ordinary shares under another, all under the company’s 2016 Equity-Based Incentive Plan.
The options for 3,000,000 ordinary shares carry an exercise price of $0.01359375 per share and expire on April 29, 2030. The options for 3,550,000 ordinary shares have an exercise price of $0.00309375 per share and expire on October 21, 2030, with 295,833 shares already vested.
The holdings also include 3,254,167 unvested restricted stock units, each representing one ordinary share subject to time-based vesting and settled in ordinary shares. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing 2,000 ordinary shares.
PURPLE BIOTECH LTD. executive Michael Schickler filed an initial ownership report showing 9,254,472 Ordinary Shares, including 6,958,334 unvested restricted stock units that vest over time and settle in Ordinary Shares. He also holds several stock options over Ordinary Shares with exercise prices between $0.10828125 and $0.00309375 per share, expiring between April 2027 and October 2030, some already vested and others vesting in quarterly installments.
PURPLE BIOTECH LTD. director Shai S. Lankry filed an initial ownership report showing a sizable equity position. He holds 3,550,000 Ordinary Shares, including 3,254,167 unvested restricted stock units that settle in shares or ADSs. He also holds stock options to purchase 3,000,000 Ordinary Shares at an exercise price of $0.01359375 per share and options to purchase 3,550,000 Ordinary Shares at $0.00309375 per share, both vesting over several years and expiring in 2030.
Purple Biotech Ltd. filed a Form 6-K to furnish a press release announcing an AI-driven collaboration with Converge Bio to advance its next-generation tri-specific antibody platform. The partnership uses Converge Bio’s generative AI to design and optimize oncology-focused antibodies, aiming to speed discovery and improve molecule quality.
Purple Biotech plans to apply these AI insights to its CAPTN-3 platform of masked tri-specific antibodies that engage both T cells and NK cells, with lead candidates IM1240 and IM1305 in preclinical development. The company also highlights additional clinical-stage assets CM24 and NT219, whose further progress depends on partnering or investment.
Purple Biotech Ltd. provides an updated corporate presentation describing its immuno-oncology pipeline and financial position. The company highlights its CAPTN-3 tri-specific antibody platform, led by IM1240 for solid tumors, with GLP toxicology planned in Q3 2026, an IND submission in Q4 2026 and first-in-human Phase 1 initiation in Q1 2027.
Two additional clinical-stage assets, CM24 for pancreatic cancer and NT219 for recurrent/metastatic head and neck cancer, have Phase 2 data and are positioned for partnerships. The company reports cash of $9.5 million and a cash runway extending into the first half of 2027, with 930K shares outstanding as of December 31, 2025.